scholarly journals Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Liver Cancer ◽  
2016 ◽  
Vol 5 (3) ◽  
pp. 175-189 ◽  
Author(s):  
Satoshi Kitai ◽  
Masatoshi Kudo ◽  
Naoshi Nishida ◽  
Namiki Izumi ◽  
Michiie Sakamoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Survival Benefit ◽  
Locoregional Treatment ◽  
Advanced Liver Cirrhosis

Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study

2015 ◽  
Vol 46 (6) ◽  
pp. 521-528 ◽  
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Kojiro Michitaka ◽  
Hidenori Toyoda ◽  
Toshifumi Tada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interventional Radiology ◽  
Liver Cirrhosis ◽  
Multicenter Study ◽  
Survival Benefit

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

Digestion ◽  
2011 ◽  
Vol 83 (4) ◽  
pp. 275-282 ◽  
Author(s):  
Kerstin Schütte ◽  
Lars Zimmermann ◽  
Jan Bornschein ◽  
Antal Csepregi ◽  
Ricarda Rühl ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Advanced Liver Cirrhosis

scholarly journals TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA ON ADVANCED LIVER CIRRHOSIS

2020 ◽  
Vol 178 (6) ◽  
pp. 29-35
Author(s):  
A. S. Polekhin ◽  
P. G. Tarazov ◽  
A. A. Polikarpov ◽  
D. A. Granov
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Survival Rate ◽  
Liver Failure ◽  
Transcatheter Arterial Chemoembolization ◽  
Intermediate Stage ◽  
Complete Response ◽  
Response To Treatment ◽  
Advanced Liver Cirrhosis ◽  
Arterial Chemoembolization

OBJECTIVE was to evaluate the results of transcatheter arterial chemoembolization (TACE) in the treatment of patients with hepatocellular carcinoma (HCC) on advanced liver cirrhosis (LC) and intermediate stage (B) according to BCLC classification (Barcelona Clinic Liver Cancer classification).METHODS AND MATERIALS. We evaluated results of TACE in 54 patients. Of them, 12 (22 %) had stage A of cirrhosis and 42 (78 %) – stage B of cirrhosis according to the Child-Pugh score. Nine (17 %) patients matched stage A4 and 45 (83 %) – stage В according to BCLC classification. The TACEs was performed according to the conventional practice with using Lipiodol + gelfoam (n=40) and with a drug-eluting beads (n=14) from 1 to 16 (average 6) times. The Doxorubicin was used as a first-line therapy in all cases.RESULTS. After TACE, two patients died of liver failure (3.7 %). According to the m-RECIST, complete response to treatment was observed in 9 (16.5 %), partial response – in 13 (24 %), stabilization – in 19 (35.5 %) and progression – in 13 (24 %) patients. At present, 22 (41 %) patients are alive for 1 to 51 (average 16.2) months. 32 patients (59 %) died between 2 to 62 months: 13 (24 %) – from HCC progression, 19 (35 %) – from liver failure. The 1– 2–3-year survival rate was 75–44–15 %; only one patient survived > 5 years. The median survival rate was (22.0±3.0) months, overall survival rate according to Kaplan – Meier was 26 months.CONCLUSION. TACE is a relatively safe and effective treatment in patients with HCC on advanced LC and intermediate stage (B). 

Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients

2003 ◽  
Vol 13 (7) ◽  
pp. 1693-1698 ◽  
Author(s):  
Wei Chiang Liu ◽  
Jae Hoon Lim ◽  
Cheol Keun Park ◽  
Min Ju Kim ◽  
Seung Hoon Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Liver Cirrhosis
Sign in / Sign up

Export Citation Format

Share Document